title: [Single nucleotide polymorphisms in cell cycle regulator p21 and p27 genes are associated with susceptibility to epithelial ovarian cancer].
abstract: OBJECTIVE
  To investigate the association of single nucleotide polymorphisms (SNP) in p21 and p27 genes with the risk of epithelial ovarian cancer (EOC).
  
  
  METHODS
  Genotypes were analyzed by polymerase chain reaction-restrictive fragment length polymorphism (PCR-RFLP) method in 234 patients with EOC and 284 control women in China.
  
  
  RESULTS
  (1) The frequencies of the p21 in healthy controls were 34.2%, 49.6% and 16.2%, while the distribution of the C and T allele was 59.0% and 41.0%, respectively. The p21 C/C (28.2%), C/T (53.0%), T/T (18.8%) distribution in ovarian cancer patients was not significantly different from that in healthy controls (P > 0.05). There was no statistic difference in allele distribution between ovarian cancer patients and healthy controls (P > 0.05) either. The stratification analysis by tumor histological type did show that the genotype distribution in four types of ovarian cancer patients was significantly different from that in healthy controls (P = 0.02) . The C/C genotype was likely to reduce the risk of epithelial endometrial cancer, and the adjusted odds ratio was 0.56 (95% CI:0.32-0.98). (2) The genotype frequencies of the p27 in healthy controls were 88.4%, 10.9% and 0.7%, while the distribution of the V and G allele was 93.8% and 6.2%, respectively. The V/V (93.6%), V/G (5.1%) and G/G (1.3%) distribution in ovarian cancer patients was significantly different from that in healthy controls (P = 0. 04). There was no statistic difference in allele distribution between ovarian cancer patients and healthy controls (P > 0.05). Compared with the V/G and G/G genotypes, the V/V genotype increased the risk of EOC, the adjusted odds ratio was 1.92 (95% CI: 1.02-3.63).
  
  
  CONCLUSIONS
  The C/C genotype of p21 may reduce the risk of epithelial endometrial cancer, and the genotype of p27 V/V may be a potential risk factor for susceptibility to EOC.
authors.affiliation: Department of Molecular Biology, Fourth Hospital, Hebei Medical University, Shijiazhuang 050011, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Jin
authors.forename: Shan
authors.initials: S
authors.lastname: Kang
authors.forename: Na
authors.initials: N
authors.lastname: Wang
authors.forename: Yan-Ping
authors.initials: YP
authors.lastname: Xing
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D002453:Cell Cycle; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics*; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000235:genetics*; D018284:Cystadenocarcinoma, Serous / Q000235:genetics / Q000473:pathology; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology; D016133:Polymerase Chain Reaction / Q000379:methods; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D055815:Young Adult
chemical_list: C493956:CDKN1A protein, human; C436291:CDKN1B protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D050760:Cyclin-Dependent Kinase Inhibitor p27